Women's Bodies, Women's Wisdom (197 page)

24
. A. Follingstad, “Estriol, the Forgotten Hormone,”
Journal of the American Medical
Association,
vol. 239, no. 1 (1978), pp. 29–39; H. Lemon, “Clinical and Experimental Aspects of the Anti-Mammary Carcinogenic Activity of Estriol,”
Frontiers of Hormonal Research,
vol. 5, no. 1 (1977), pp. 155–73; H. Lemon, “Estriol Prevention of Mammary Carcinoma Induced by 7, 12-Dimethyibenza-thracene and Procarbazine,”
Cancer Research,
vol. 35 (1975), pp. 1341–53; H. Lemon, “Oestriol and Prevention of Breast Cancer,”
The Lancet,
vol. 1, no. 802 (1973), pp. 546–47; H. Lemon, “Pathophysiologic Considerations in the Treatment of Menopausal Patients with Oestrogens: The Role of Oestriol in the Prevention of Mammary Cancer,”
Acta Endocrinologica,
vol. 233, Suppl. (1980), pp. 17–27; H. Lemon, H. Wortiz, L. Parsons, et al., “Reduced Estriol Excretion in Patients with Breast Cancer Prior to Endocrine Therapy,”
Journal of the American
Medical Association,
vol. 196 (1966), pp. 1128–36; B. G. Wren and J. A. Eden, “Do Progesterones Reduce the Risk of Breast Cancer? A Review of the Evidence,”
Menopause: The Journal of the North American Menopause Society,
vol. 3, no. 1 (1996), pp. 4–12; M. van Haaften, G. H. Donker, A. A. Haspeis, et al., “Oestrogen Concentrations in Plasma, Endometrium, Myometrium, and Vagina of Postmenopausal Women, and Effects of Vaginal Oestriol (E3) and Oestradiol (E2) Applications,”
Journal of Steroid Biochemistry,
vol. 4A (1989), pp. 647–53.

25
. M. Melamed et al., “Molecular and Kinetic Basis for the Mixed Agonist/ Antagonist Activity of Estriol,”
Molecular Endocrinology,
vol. 11, no. 12 (Nov. 1997), pp. 1868–78.

26
. L. Rajkumar et al., “Prevention of Mammary Carcinogenesis by Short-Term Estrogen and Progestin Treatments,”
Breast Cancer Research,
vol. 6, no. 1 (2004), pp. R31–37.

27
. S. Granberg et al., “The Effects of Oral Estriol on the Endometrium in Postmenopausal Women,”
Maturitas,
vol. 42, no. 2 (June 25, 2002), pp. 149–56.

28
. K. Takahashi et al., “Efficacy and Safety of Oral Estriol for Managing Postmenopausal Symptoms,”
Maturitas,
vol. 34, no. 2 (Feb. 15, 2000), pp. 169–77; K. Takahashi et al., “Safety and Efficacy of Oestriol for Symptoms of Natural or Surgically Induced Menopause,”
Human Reproduction,
vol. 15, no. 5 (May 2000), pp. 1028–36.

29
. R. Punnonen and L. Raurama, “The Effect of Longterm Oral Oestriol Succinate Therapy on the Skin of Castrate Women,”
Annals of Gynecology,
vol. 66 (1977), p. 214.

30
. Hargrove and Eisenberg, “Menopause.”

31
. Ibid.

32
. F. Z. Stanczyk, R. J. Paulson, and S. Roy, “Percutaneous Administration of Progesterone: Blood Levels and Endometrial Protection,”
Menopause,
vol. 12, no. 2 (March 2005), pp. 232–37.

33
. F. Labrie et al., “Effect of Intravaginal Dehydroepiandrosterone (Prasterone) on Libido and Sexual Dysfunction in Postmenopausal Women,”
Menopause,
vol. 16, no. 5 (September-October 2009), pp. 923–31.

34
. A. Wright, “An Ethnography of the Navajo Reproductive Cycle,”
American Indian
Quarterly,
vol. 6, nos. 1–2 (Spring/Summer 1982), pp. 52–70; also quote in A. Voda, M. Dinnerstein, and C. R. O’Donnell, eds.,
Changing Perspectives on
Menopause
(Austin: University of Texas Press, 1982).

35
. J. K. Brown and V. Kerns, eds.,
In Her Prime: A New View of Middle-Aged
Women
(Amherst, MA: Bergin and Garvey, 1985).

36
. F. Kronenberg and J. A. Downey, “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”
Canadian Journal of Physiological Pharmacology,
vol.

65 (1987), pp. 1312–24.

37
. R. S. Finkler, “The Effect of Vitamin E in the Menopause,”
Journal of Clinical Endocrinology
and Metabolism,,
vol. 9 (1949), pp. 89–94.

38
. C. J. Smith, “Non-Hormonal Control of Vasomotor Flushing in Menopausal Patients,”
Chicago Medicine,
vol. 67, no. 5 (1964), pp. 193–95.

39
. C. A. B. Clemetson, S. J. DeCarol, G. A. Burney, et al., “Estrogens in Food: The Almond Mystery,”
International Journal of Gynecology and Obstetrics,
vol. 15 (1978), pp. 515–21; S. O. Elakovich and J. Hampton, “Analysis of Couvaestrol, a Phytoestrogen, in Alpha Tablets Sold for Human Consumption,”
Journal of Agricultural
and Food Chemistry,
vol. 32 (1984), pp. 173–75.

40
. H. Aldercreutz et al., “Dietary Phyto-Oestrogens and the Menopause in Japan,”

The Lancet,
vol. 339 (1992), p. 1233; M. J. Messina, V. Persky, K. D. R. Setchel, et al., “Soy Intake and Cancer Risk: A Review of the In Vitro and In Vivo Data,”

Nutrition and Cancer,
vol. 21 (1994), pp. 113–31; and G. Wilcox et al., “Oestro-genic Effects of Plant Foods in Postmenopausal Women,”
British Medical Journal,
vol. 301 (1990), pp. 905–6.

41
. S. Basaria et al., “Effect of High-Dose Isoflavones on Cognition, Quality of Life, Androgens, and Lipoprotein in Post-Menopausal Women,”
Journal of Endocrino-logical
Investigation,
vol. 32, no. 2 (February 2009), pp. 150-55.

42
. M. Murray, “HRT vs. Remifemin in Menopause,”
American Journal of Natural
Medicine,
vol. 3, no. 4 (1996), pp. 7–10; G. Warnecke, “Beeinflussing Klimakter-ischer Beschwerden durch ein Phytotherapeutikum [Influencing Menopausal Symptoms with a Phytotherapeutic Agent],”
Medwelt,
vol. 36 (1985), pp. 871–74.

43
. W. Wuttke, D. Seidlová-Wuttke, and C. Gorkow, “The Cimicifuga Preparation BNO 1055 vs. Conjugated Estrogens in a Double-Blind Placebo-Controlled Study: Effects on Menopause Symptoms and Bone Markers,”
Maturitas,
vol. 44, suppl. 1 (March 14, 2003), pp. S67–77; G. Hernandez Munoz and S. Pluchino, “
Cimicifuga racemosa
for the Treatment of Hot Flushes in Women Surviving Breast Cancer,”
Maturitas,
vol. 44, suppl. 1 (March 14, 2003), pp. S59–65.

44
. I. I. Bukham and O. I. Kirillov, “Effect of Eleutherococus on Alarm-Phase of Stress,”
Annual Review of Pharmacology,
vol. 8 (1969), pp. 113–21; A. Milewiez, E. Gejdel, et al., “Vitex Agnus Castus Extract in the Treatment of Luteal Phase Defects Due to Hyperprolactinemia: Results of a Randomized Placebo-Controlled Double-Blind Study,”
Arzneimittel-Forschung/Drug Research,
vol. 43 (1993), pp.

752–56; D. B. Mowrey,
The Scientific Validation of Herbal Medicine
(New Canaan, CT: Keats, 1986); G. Sliutz, P. Speiser, et al., “Agnus Castus Extracts Inhibit Prolactin Secretion of Rat Pituitary Cells,”
Hormone and Metabolic Research,
vol. 2 (1993), pp. 253–55.

45
. S. E. Geller et al., “Safety and Efficacy of Black Cohosh and Red Clover for the Management of Vasomotor Symptoms: A Randomized Controlled Trial,”
Menopause
(July 15, 2009), [Epub ahead of print].

46
. P. M. Maki et al., “Effects of Botanicals and Combined Hormone Therapy on Cognition in Postmenopausal Women,”
Menopause
(July 31, 2009), [Epub ahead of print].

47
. J. Tan Garcia et al., “Use of a Multibotanical (Nutrafem) for the Relief of Menopausal Vasomotor Symptoms: A Double-Blind, Placebo-Controlled Study,”
Menopause
(November 19, 2009), [Epub ahead of print].

48
. J. Manonai et al., “Effects and Safety of
Pueraria mirifica
on Lipid Profiles and Biochemical Markers of Bone Turnover Rates in Healthy Postmenopausal Women,”
Menopause,
vol. 15, no. 3 (May–June 2008), pp. 530–35; N. Urasopon et al., “
Pueraria mirifica,
a Phytoestrogen-Rich Herb, Prevents Bone Loss in Or-chidectomized Rats,”
Maturitas,
vol. 56, no. 3 (March 20, 2007), pp. 322–31.

49
. V. Chandeying and M. Sangthawan, “Efficacy Comparison of
Pueraria mirifica
(PM) Against Conjugated Equine Estrogen (CEE) With/Without Medroxyproges-terone Acetate (MPA) in the Treatment of Climacteric Symptoms in Peri-menopausal Women: Phase III Study,”
Journal of the Medical Association of
Thailand,
vol. 90, no. 9 (September 2007), pp. 1720–6.

50
. S. Ramnarine, J. MacCallum, and M. Ritchie, “Phyto-oestrogens: Do They Have a Role in Breast Cancer Therapy?”
Proceedings of the Nutrition Society,
vol. 68 (OCE) (2009), p. E93.

51
. T. Hudson, “Maca: New Insights on an Ancient Plant,”
Integrative Medicine,
vol. 7, no. 6 (Dec. 2008/Jan. 2009), pp. 54–57.

52
. J. R. Lee,
What Your Doctor May Not Tell You About Menopause
(New York: Warner Books, 1996).

53
. L. M. Germaine and R. R. Freedman, “Behavioral Treatment of Menopausal Hot Flashes: Evaluation by Objective Methods,”
Journal of Consulting and Clinical
Psychology,
vol. 52 (1984), pp. 1072–9; R. R. Freedman and S. Woodward, “Behavioral Treatment of Menopausal Hot Flushes: Evaluation by Ambulatory Monitoring,”
American Journal of Obstetrics and Gynecology,
vol. 167 (1992), pp. 436–39; R. R. Freedman et al., “Biochemical and Thermoregulatory Effects of Behavioral Treatment for Menopausal Hot Flashes,”
Menopause,
vol. 2 (1995), pp. 211–18; J. H. Irvin et al., “The Effects of Relaxation Response Training on Menopausal Symptoms,”
Journal of Psychosomatic Obstetrics and Gynaecology,
vol. 17 (1996), pp. 202–7; K. Wijima et al., “Treatment of Menopausal Symptoms with Applied Relaxation: A Pilot Study,”
Journal of Behavior Therapy and Experimental
Psychiatry,
vol. 28 (1997), pp. 251–61.

54
. A. D. Domar and H. Dreher,
Healing Mind, Healthy Woman
(New York: Henry Holt and Co., 1996), pp. 291–92; Swartzman, “Impact of Stress”; Freedman and Woodward, “Behavioral Treatment of Menopausal Hot Flushes: Evaluation by Ambulatory Monitoring”; L. C. Swartzman, R. Edelberg, and E. Kemmann, “The Menopausal Hot Flush: Symptom Reports and Concomitant Physical Changes,”
Journal of Behavioral Medicine,
vol. 13 (1990), pp. 15–30; D. W. Stevenson and D. J. Delprato, “Multiple Component Self-Control Program for Menopausal Hot Flashes,”
Journal of Behavior Therapy and Experimental Psychology,
vol. 14, no. 2 (1983), pp. 137–40.

55
. N. Carroll et al., “Postmenopausal Restoration of the Estradiol/Estrone Ratio Reduces Severity of Vasomotor Symptoms,” presented at the 57th Annual Meeting of the American College of Obstetricians and Gynecologists, May 2009, Chicago, IL.

56
. M. Freedman et al., “Twice-Weekly Synthetic Conjugated Estrogens Vaginal Cream for the Treatment of Vaginal Atrophy,”
Menopause,
vol. 16, no. 4 (July/August 2009), pp. 735–41.

57
. S. Weed,
Menopausal Years: The Wise Women’s Way: Alternative Approaches for
Women 30–90
(Woodstock, NY: Ash Tree Publishing, 1992).

58
. M. Bygdeman and M. L. Swahn, “Replens Versus Dienoestrol Cream in Symptomatic Treatment of Vaginal Atrophy in Postmenopausal Women,”
Maturitas,
vol. 23 (1996), pp. 256–63.

59
. Susan Rako, M.D.,
The Hormone of Desire: The Truth About Sexuality,
Menopause, and Testosterone
(New York: Harmony, 1996).

60
. V. L. Handa, “Vaginal Administration of Low-Dose Conjugated Estrogens: Systemic Absorption and Effects of the Endometrium,”
Obstetrics and Gynecology,
vol. 84 (1994), pp. 215–18; G. M. Heimer and E. L. E. Englund, “Effects of Vaginally Administered Oestriol on Postmenopausal Urogenital Disorders: A Cytohor-monal Study,”
Maturitas,
vol. 3 (1992), pp. 171–79; C. S. Iosif, “Effects of Protracted Administration of Estriol on the Lower Urinary Tract in Postmenopausal Women,”
Archives of Gynecology and Obstetrics,
vol. 3, no. 251 (1992), pp. 115–20; A. L. Kirkengen, P. Anderson, E. Gjersoe, et al., “Oestriol in the Prophylactic Treatment of Recurrent Urinary Tract Infections in Postmenopausal Women,”
Scandinavian Journal of Primary Health Care,
(June 1992), pp. 139–42; R. Ruz and W. Stamm, “A Controlled Trial of Intravaginal Estriol in Post-Menopausal Women with Recurrent Urinary Tract Infections,”
New England
Journal of Medicine,
vol. 329, no. 11 (1993), pp. 753–56. M. van Haaften et al., “Oestrogen Concentrations in Plasma, Endometrium, Myo metrium, and Vagina of Postmenopausal Women, and Effects of Vaginal Oestriol (E3) and Oestradiol (E2) Applications,”
Journal of Steroid Biochemistry,
vol. 4A (1989), pp. 647–53.

61
. D. Michaelson, C. Stratakis, L. Hill, et al., “Bone Mineral Density in Women with Depression,”
New England Journal of Medicine,
vol. 335, no. 16 (October 17, 1996), pp. 1176–81.